Show simple item record

Natural HPV immunity and vaccination strategies.

dc.contributor.authorStern, Peter L
dc.contributor.authorBrown, Michael D
dc.contributor.authorStacey, Simon N
dc.contributor.authorKitchener, Henry C
dc.contributor.authorHampson, Ian N
dc.contributor.authorAbdel-Hady, El-Said
dc.contributor.authorMoore, James V
dc.date.accessioned2009-11-13T12:57:27Z
dc.date.available2009-11-13T12:57:27Z
dc.date.issued2000-10
dc.identifier.citationNatural HPV immunity and vaccination strategies. 2000, 19 (1-2):57-66 J. Clin. Virol.en
dc.identifier.issn1386-6532
dc.identifier.pmid11091148
dc.identifier.urihttp://hdl.handle.net/10541/86138
dc.description.abstractBACKGROUND: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. OBJECTIVES: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. CONCLUSION: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia.
dc.language.isoenen
dc.subjectVulvar Canceren
dc.subjectTumour Virus Infectionsen
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunity, Innate
dc.subject.meshOncogene Proteins, Viral
dc.subject.meshPapillomaviridae
dc.subject.meshPapillomavirus Infections
dc.subject.meshTumor Virus Infections
dc.subject.meshVaccination
dc.subject.meshViral Vaccines
dc.subject.meshVulvar Neoplasms
dc.titleNatural HPV immunity and vaccination strategies.en
dc.typeArticleen
dc.contributor.departmentDepartment of Immunology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, M20 4BX, Manchester, UK.en
dc.identifier.journalJournal of Clinical Virologyen
html.description.abstractBACKGROUND: the task of preventing premature death in women may be delivered by vaccinating against the high-risk papillomaviruses associated with various malignancies. OBJECTIVES: we will discuss the immune mechanisms likely to be relevant to the control of an HPV infection in the cervix and assess the limited evidence for such immune recognition in the natural history of infection. CONCLUSION: the next generation of vaccination strategies should include the use of HPV 16 early (E2 and/or E6 and/or E7) and late gene targets (L1 and L2) expressed as VLPs with their clinical and immunological evaluation aimed at therapy as well as prophylaxis. Important clinical efficacy assessment may be deliverable in relatively short-term studies by targeting patients with HPV 16 associated vulval intraepithelial neoplasia.


This item appears in the following Collection(s)

Show simple item record